Is Kailera Therapeutics, Inc. overvalued?

Kailera Therapeutics, Inc. (KLRA) — key valuation metrics and fundamentals.

No verdict

Price

$11.23

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$1.45B

Dividend yield

0.0%

Return on equity

-55.4%

Sector

Healthcare

Fair value compares KLRA's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.

Related stocks